Oncology Overview: Treatment of Chronic Lymphocytic Leukemia with Ibrutinib, Venetoclax
August 16th 2022Both ibrutinib (Imbruvica) and venetoclax (Venclexta) carry an approved indication for use in chronic lymphocytic leukemia but do not often lead to complete remission, and therapy routinely continues indefinitely or until disease progression.
Read More